Longevity target · graded by use, two uses
Sleep as a Longevity Intervention
Graded on: cardiometabolic markers and energy intake after sleep extension in short sleepers.
Grade C: human trials exist, but they are small, mixed or not yet repeated. This is not a finding that it does not work. How to read a grade →
Compare this record with another, side by side →
How this letter has changedLatest: October 2026 · Downgraded.
The B leaned on an observational Research that watches what people already do rather than assigning a treatment. It can show that two things travel together, not that one causes the other. mortality meta-analysis A study that pools the numbers from several trials into one combined estimate. (Cappuccio et al., Sleep, 2010; PMID PubMed ID: the permanent number the US National Library of Medicine gives a published paper. Each one links to that paper's record on PubMed. 20469800), and EBL never grades on observational data. Without it, the graded evidence is sleep extension trials on surrogate markers A lab value or measurement used in place of the outcome that matters, such as LDL cholesterol standing in for heart attacks. Moving a surrogate does not always move the outcome.. A PubMed search found them mixed: Zhu et al. (Eur J Cardiovasc Nurs, 2022; PMID 34279625) found no overall change in blood pressure, glucose or insulin resistance, and Beals et al. (Diabetes Care, 2026; PMID 41564347) found no change in clamp-measured insulin sensitivity. Tasali et al. (JAMA Intern Med, 2022; PMID 35129580) found lower energy intake in one trial. Mixed or unreplicated results are the written C definition. The descriptions of Gonzales 2022 and Hartescu 2022 were also corrected.PMID 20469800 PMID 34279625 PMID 41564347 PMID 35129580
Every change to a letter on this site is dated and published. The full evidence log →
This record looks at sleeping more as a health target. In people who usually sleep too little, small studies added about an hour of sleep a night. Some found lower blood pressure or better blood sugar, while others found no change. In one study of adults with extra weight, sleeping more led them to eat about 270 fewer calories a day.
All two uses graded on this record carry a C, each on its own evidence.
As studied, and the trials
Falls from B to C. Zhu et al. (Eur J Cardiovasc Nurs, 2022; PMID 34279625) found no overall change in blood pressure, fasting glucose or insulin resistance; the best-measured trial, Beals et al. (Diabetes Care, 2026; PMID 41564347), found no change in clamp-measured insulin sensitivity; Hartescu et al. (J Sleep Res, 2022; PMID 34459060) was positive in 18 men. Mixed results on surrogate markers: C.
As studied, and the trials
Tasali et al. (JAMA Intern Med, 2022; PMID 35129580): energy intake measured by doubly labeled water fell by 270 kcal a day against control, with weight lower. One unblinded single-center trial that nobody has independently repeated: C.
Read the grade that matches your goal. How EBL grades by use →
Lifestyle intervention · Recovery · Neurological
A letter describes the human evidence, not the product, the manufacturer, or the intervention's worth.
See the full evidence record →In large cohort studies An observational study that follows a group of people over time and compares what happens to them., short sleep (below 6 hours a night) is associated with 12 percent higher all-cause mortality and with cardiovascular disease, type 2 diabetes, obesity and cognitive decline. Those are associations, and EBL does not grade on them. The trials that lengthened sleep in short sleepers found mixed effects on blood pressure and glucose, and one found lower energy intake, which is why the letter is C. Sleep is not a passive state. It is when the brain clears metabolic waste via the glymphatic system, when growth hormone peaks, when memory consolidation occurs, and when the immune system resets. No supplement on this platform compensates for chronic sleep deprivation.
| Evidence-based target | 7 to 9 hours per night for most adults. Below 6 hours and above 9 hours are both independently associated with increased mortality in cohort data. |
| CBT-I | Cognitive Behavioral Therapy for Insomnia is the first-line treatment for chronic insomnia, graded on its own protocol record. More effective than sleep medications for long-term outcomes. Available via trained therapists or digitally (Sleepio, CBTI Coach app). |
| Melatonin | Graded use by use on the melatonin supplement page, with the doses each trial used. |
| Magnesium | Graded use by use on the magnesium supplement page. |
| Sleep tracking | Oura Ring and WHOOP provide reasonable sleep stage estimates. Sleep tracking can increase sleep anxiety, which works against sleep. The goal is behavioral change, not perfect data. |
| Critical error | Most people optimize supplements, devices, and protocols while sleeping 5 to 6 hours. EBL prioritizes sleep quality and duration above every other longevity intervention. |
Total sleep time (target 7 to 9 hours). Sleep efficiency (time asleep divided by time in bed, target above 85%). Subjective sleep quality (1 to 10 scale daily). Wearable sleep stage data if available and not anxiety-provoking. Morning resting HRV as a proxy for recovery quality overnight.
Sleep extension trials in free-living adults. Overall, blood pressure, fasting glucose and insulin resistance did not change significantly; blood pressure fell only in a subgroup with raised pressure.
About an hour more sleep a night for 6 weeks improved sleep but did not change insulin sensitivity measured by clamp, or glucose control.
Adults with overweight who slept under 6.5 hours were counseled to sleep longer. Sleep rose by about 1.2 hours a night and energy intake fell by about 270 kcal a day against control. One trial, not yet repeated.
Meta-analysis of 16 prospective studies including 1.3 million participants. Short sleep duration (below 6 hours) was associated with a 12 percent increase in all-cause mortality and significantly increased cardiovascular mortality. A dose-response relationship was confirmed.
Review of how sleep and the immune system regulate each other, covering cytokine responses, the hormonal and nerve pathways between them, and how disturbed sleep is linked to inflammatory and antiviral responses. A review, not a trial.
Meta-analysis of 15 studies of cognitive behavioral therapy for insomnia measuring sleep objectively. No reliable improvement in sleep measured by polysomnography; actigraphy showed a small reduction in time to fall asleep. Sleep diaries improved robustly, so the benefit shows more in reported sleep than in measured sleep.
CBT-I has no safety concerns. Sleep medications (benzodiazepines, Z-drugs) carry significant dependency and cognitive risks with long-term use. The melatonin record states the doses used in the trials.
Many medications impair sleep quality: beta-blockers (suppress melatonin, reduce REM), SSRIs and SNRIs (suppress REM, cause vivid dreams), corticosteroids (stimulating, disrupt sleep architecture), stimulant ADHD medications (delay sleep onset), decongestants (stimulating). If sleep quality deteriorated after starting a medication, discuss with your prescriber.
The evidence places sleep upstream of most of what this platform grades. Someone sleeping 5.5 hours a night while taking 15 supplements is varying the smaller term. Across the insomnia literature, CBT-I (including digital delivery such as the Sleepio program) carries the strongest human evidence of the available options. How any of that applies to you is a decision for you and your physician.
Educational use only · Not medical advice · Starting, stopping or changing any supplement or medication is a decision for your physician
EBL does not verify the regulatory status of any device. Many consumer wellness devices are not FDA-cleared The FDA found a device substantially equivalent to one already on the market. Clearance is not approval and does not require trials showing benefit., and FDA clearance, where it exists, applies only to specific indications. The grade on this page describes the strength of published human trial evidence in the populations studied. It is not a recommendation for any individual and is not medical advice. Using any device for a health purpose is a decision for your physician.
Primary evidenceSix papers, each linked to its PubMed record.
Zhu et al. (European Journal of Cardiovascular Nursing, 2022; PMID 34279625): 13 reports from 11 sleep extension trials; overall no significant change in blood pressure, fasting glucose or insulin resistance, with lower blood pressure only in a subgroup with raised pressure. Beals et al. (Diabetes Care, 2026; PMID 41564347): 29 short sleepers given about an hour more sleep a night for 6 weeks; no change in clamp-measured insulin sensitivity or glucose control. Hartescu et al. (Journal of Sleep Research, 2022; PMID 34459060): 18 overweight or obese men, 6 weeks; blood pressure and HOMA-IR fell, in a trial too small to change a grade. Gonzales et al. (Sleep Medicine, 2022; PMID 35180478): 12 middle-aged adults who were not short sleepers, five nights of extended time in bed; blood pressure and arterial stiffness unchanged, forearm vascular capacity higher. Tasali et al. (JAMA Internal Medicine, 2022; PMID 35129580): 80 adults with overweight who slept under 6.5 hours; about 1.2 hours more sleep and 270 kcal a day less energy intake, in one unblinded trial. Mixed and unreplicated results on surrogate markers: Grade C. Mortality: no randomized trial has tested sleep extension against death. The link between sleep length and mortality comes from cohorts (Cappuccio et al., Sleep, 2010; PMID 20469800; short sleep RR 1.12, long sleep RR 1.30, sleep self-reported), and observational data never carries a grade.
This page carries a letter. EBL takes no commission, referral fee or payment of any kind on anything it grades. No letter has been bought and none is for sale. Products listed under this modality may be commercial partners, and their purchase links may earn EBL a commission. Those products carry no letter of their own, every relationship is disclosed beside the link, and where a product does not deliver what the trials tested, this page says so regardless of who pays.
How this is enforced
That is not a promise, it is a build condition. Two checks run on every deploy: one refuses to publish if a commission is claimed on anything graded, the other refuses if a page names a commercial relationship that is not declared in the register. If either fails, this page does not go live. You can read how the checks work, and what they do not cover, on the evidence integrity page.
These statements have not been evaluated by the Food and Drug Administration. Any grade on this page describes the strength of published human trial evidence in the populations studied. It is not a recommendation for any individual and is not medical advice. Starting, stopping or changing any supplement or medication is a decision for your physician.
How EBL searched for the trials (1 search)
The search that was run, what it returned, and what was left out and why, so the absence of evidence can be checked as well as its presence.
("sleep extension"[tiab] OR "extending sleep"[tiab] OR "extended sleep"[tiab] OR "increase sleep duration"[tiab] OR "increasing sleep duration"[tiab]) AND ("blood pressure"[tiab] OR insulin[tiab] OR glucose[tiab] OR cardiometabolic[tiab] OR metabolic[tiab] OR mortality[tiab] OR weight[tiab] OR "energy intake"[tiab]) AND (meta-analysis[pt] OR randomized controlled trial[pt])Grades move when new trials publish. A free monthly email lists every grade EBL moved, with the reason and the trial behind it: the sign-up is on the Evidence Log →